drugset / Trial / NCT01285232

The Effect of Anakinra on Insulin Secretion

NCT01285232

Unknown 16 enrolled Radboud University Medical Center
RandomizedCrossoverTriple-blind

Summary

Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus. Recent findings suggest that interleukin-1 (IL-1) may be involved in the progressive β-cell dysfunction in type 2 diabetes mellitus. Objective: to determine whether blocking IL-1β by recombinant human IL-1ra (anakinra) improves beta-cell function in subjects with β-cell dysfunction.

Timeline

Start
2011-01
Primary completion
2012-03
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 150 mg Subcutaneous